Cayston
Cayston is an inhaled monobactam antibacterial drug. It is reconstituted and administered using the Altera Nebulizer System to deliver aztreonam directly to the airways, targeting Pseudomonas aeruginosa infections in individuals with cystic fibrosis.
Dosage by Body Weight
The standard dose for adults and pediatric patients aged 7 years and older is 75 mg (one reconstituted vial) administered 3 times daily for a 28-day course, followed by 28 days off therapy. Doses should be spaced at least 4 hours apart.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients under 7 years of age.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients under 7 years of age.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients under 7 years of age.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients under 7 years of age.
- Body Weight
- 16-20 kg
- Dose
- 75 mg (if age is 7 years or older)
- Frequency
- 3 times daily
- Tracking Notes
- Dosing is age-based rather than weight-based. Cayston is not approved for children under 7 years of age.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients under 7 years of age. |
| 5-7 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients under 7 years of age. |
| 8-10 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients under 7 years of age. |
| 11-15 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients under 7 years of age. |
| 16-20 kg | 75 mg (if age is 7 years or older) | 3 times daily | Dosing is age-based rather than weight-based. Cayston is not approved for children under 7 years of age. |
Formulation
Inhalation Powder for ReconstitutionInhalation Solution
Purpose
To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections.
Generic Name
Aztreonam lysineScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.